Institution · Lung Institute
Most cited papers from Lung Institute
What are the most cited papers from Lung Institute?
The most cited paper from Lung Institute is "Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge" (William T. Friedewald, Robert I. Levy, Donald S. Fredrickson, 1972), with 32,670 citations. Next come "A map of human genome variation from population-scale sequencing" (8,156) and "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure" (6,982).
Showing 50 of 60 papers. Every paper with more than 1,079 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge William T. Friedewald, Robert I. Levy, Donald S. Fredrickson · Clinical Chemistry | Jun 1972 | 32,670 |
| 2 | A map of human genome variation from population-scale sequencing Richard M. Durbin et al. · Nature | 26 Oct 2010 | 8,156 |
| 3 | Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure John J.V. McMurray, Milton Packer, Akshay Suvas Desai et al. · New England Journal of Medicine | 30 Aug 2014 | 6,982 |
| 4 | Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz et al. · Circulation | 12 Jul 2004 | 6,936 |
| 5 | Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research Carol Kilkenny, William J. Browne, Innes C. Cuthill et al. · Journal of Pharmacology and Pharmacotherapeutics | 10 Nov 2010 | 6,366 |
| 6 | Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease Marc Steven Sabatine, Robert Patrick Giugliano, ANTHONY C. KEECH et al. · New England Journal of Medicine | 17 Mar 2017 | 6,185 |
| 7 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy | 2 Jan 2016 | 6,023 |
| 8 | Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis Luca Richeldi et al. · New England Journal of Medicine | 18 May 2014 | 4,731 |
| 9 | Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases Peter John Barnes, Michael Karin · New England Journal of Medicine | 10 Apr 1997 | 4,699 |
| 10 | A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease Patrick W. Serruys, Peter de Jaegere, Ferdinand Kiemeneij et al. · New England Journal of Medicine | 25 Aug 1994 | 4,563 |
| 11 | International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Kian Fan Chung et al. · European Respiratory Journal | 12 Dec 2013 | 3,995 |
| 12 | Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome Gregory G. Schwartz et al. · New England Journal of Medicine | 7 Nov 2018 | 3,654 |
| 13 | The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research Nathalie Percie du Sert et al. · Experimental Physiology | 14 Jul 2020 | 3,555 |
| 14 | Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Deepak L. Bhatt, Philippe Gabríel Steg, Michael J. Miller et al. · New England Journal of Medicine | 10 Nov 2018 | 3,331 |
| 15 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary Claus Franz Vogelmeier et al. · American Journal of Respiratory and Critical Care Medicine | Mar 2017 | 3,296 |
| 16 | Transcatheter Mitral-Valve Repair in Patients with Heart Failure Gregg W. Stone, JoAnn M. Lindenfeld, William T. Abraham et al. · New England Journal of Medicine | 23 Sep 2018 | 2,986 |
| 17 | Type I interferons in infectious disease Finlay W. McNab, Katrin D. Mayer-Barber, Alan Sher et al. · Nature reviews. Immunology | 23 Jan 2015 | 2,863 |
| 18 | Predominant TH2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma Douglas S. Robinson, Qutayba A. Hamid, Sun Ying et al. · New England Journal of Medicine | 30 Jan 1992 | 2,772 |
| 19 | Nintedanib in Progressive Fibrosing Interstitial Lung Diseases Kevin R. Flaherty, Athol Umfrey Wells, Vincent Cottin et al. · New England Journal of Medicine | 29 Sep 2019 | 2,440 |
| 20 | Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Scott David Solomon et al. · New England Journal of Medicine | Sep 2019 | 2,429 |
| 21 | Role of diabetes in congestive heart failure: The Framingham study William B. Kannel, Marthana C. Hjortland, William P. Castelli · The American Journal of Cardiology | Jul 1974 | 2,117 |
| 22 | Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency Stefan D. Anker, Josep Comín Colet, Gerasimos S Filippatos et al. · New England Journal of Medicine | 17 Nov 2009 | 2,090 |
| 23 | Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk Georg Ehret et al. · Nature | 9 Sep 2011 | 2,085 |
| 24 | A Large-Scale, Consortium-Based Genomewide Association Study of Asthma Miriam F. Moffatt, Ivo Glynne Gut, Florence Démenais et al. · New England Journal of Medicine | 22 Sep 2010 | 2,069 |
| 25 | Microtubule Assembly in the Absence of Added Nucleotides Michael L. Shelanski, Felicia Gaskin, Charles R. Cantor · Proceedings of the National Academy of Sciences | Mar 1973 | 2,062 |
| 26 | Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction Marc P. Bonaca et al. · New England Journal of Medicine | 14 Mar 2015 | 2,003 |
| 27 | Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents Laura Mauri et al. · New England Journal of Medicine | 16 Nov 2014 | 1,928 |
| 28 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Philip Alexander Poole-Wilson, Karl B Swedberg, John G.F. Cleland et al. · The Lancet | Jul 2003 | 1,877 |
| 29 | Disordered Microbial Communities in Asthmatic Airways Markus Hilty, Conor M. Burke, Helder Pedro et al. · PLoS ONE | 4 Jan 2010 | 1,873 |
| 30 | Cells of the adult human heart Monika Litviňuková et al. · Nature | 24 Sep 2020 | 1,845 |
| 31 | Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) Claire L. Shovlin, Alan E. Guttmacher, Elisabetta Buscarini et al. · American Journal of Medical Genetics | 6 Mar 2000 | 1,760 |
| 32 | ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. IV. PROTECTIVE ROLE OF GLUTATHIONE J.R. Mitchell, David J. Jollow, William Z. Potter et al. · Journal of Pharmacology and Experimental Therapeutics | Oct 1973 | 1,755 |
| 33 | Inflammatory mechanisms in patients with chronic obstructive pulmonary disease Peter John Barnes · Journal of Allergy and Clinical Immunology | 27 May 2016 | 1,713 |
| 34 | Asthma: From Bronchoconstriction to Airways Inflammation and Remodeling Jean Bousquet, Peter K. Jeffery, WILLIAM W. BUSSE et al. · American Journal of Respiratory and Critical Care Medicine | May 2000 | 1,710 |
| 35 | SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract Yixuan Jacob Hou et al. · Cell | 26 May 2020 | 1,680 |
| 36 | Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms Peter John Barnes · Clinical Science | Jun 1998 | 1,587 |
| 37 | Exposure to Environmental Microorganisms and Childhood Asthma Markus Johannes Ege, M. Mayer, Anne‐Cécile Normand et al. · New England Journal of Medicine | 23 Feb 2011 | 1,553 |
| 38 | Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma ROMAIN A. PAUWELS, Claes-Göran Löfdahl, Dirkje Sjoukje Postma et al. · New England Journal of Medicine | 13 Nov 1997 | 1,524 |
| 39 | Truncations of Titin Causing Dilated Cardiomyopathy Daniel S. Herman et al. · New England Journal of Medicine | 15 Feb 2012 | 1,514 |
| 40 | Chronic obstructive pulmonary disease: molecular and cellularmechanisms Peter John Barnes, SD Shapiro, Ruben Pauwels · European Respiratory Journal | Oct 2003 | 1,443 |
| 41 | Immunology of asthma and chronic obstructive pulmonary disease Peter John Barnes · Nature reviews. Immunology | 15 Feb 2008 | 1,407 |
| 42 | Wasting as independent risk factor for mortality in chronic heart failure Stefan D. Anker, Piotr P. Ponikowski, Susan J. Varney et al. · The Lancet | Apr 1997 | 1,406 |
| 43 | Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy Stephen R. Durham, Samantha M Walker, Eva‐Maria Varga et al. · New England Journal of Medicine | 12 Aug 1999 | 1,380 |
| 44 | Allergy and Allergic Diseases A.B. Kay · New England Journal of Medicine | 4 Jan 2001 | 1,377 |
| 45 | Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals Nathalie Conrad, Andrew Judge, Jenny Tran et al. · The Lancet | 22 Nov 2017 | 1,360 |
| 46 | Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria Edward A. Miao, Irina A. Leaf, Piper M. Treuting et al. · Nature Immunology | 7 Nov 2010 | 1,356 |
| 47 | Guidelines for performing Mendelian randomization investigations Stephen Burgess, George Davey Smith, Neil M Davies et al. · Wellcome Open Research | 28 Apr 2020 | 1,354 |
| 48 | The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic Geoffrey D. Rubin et al. · CHEST Journal | 7 Apr 2020 | 1,306 |
| 49 | Exhaled breath condensate: methodological recommendations and unresolved questions Ildikó Horváth, John Francis Hunt, Peter John Barnes · European Respiratory Journal | 31 Aug 2005 | 1,289 |
| 50 | Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms Cecilia M. Linde, William T. Abraham, Michael Robert Gold et al. · Journal of the American College of Cardiology | 9 Nov 2008 | 1,268 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.